At a glance
| Abbreviation | HPV18, HPV39, HPV45, HPV59 |
|---|---|
| ICTV species | Alphapapillomavirus 7 |
| Family | Papillomaviridae |
| Baltimore class | I — dsDNA |
| Human infection | Human infection recorded; pattern not classified |
Also called: human papillomavirus 39; human papillomavirus 45; human papillomavirus 59; human papillomavirus 68; human papillomavirus 70; human papillomavirus 85; human papillomavirus 97; Alphapapillomavirus 7
Floreoviria › Cossaviricota › Papovaviricetes › Zurhausenvirales › Papillomaviridae › Alphapapillomavirus
What it is
Taxonomy copied from ICTV MSL41.v1 / VMR_MSL41.v1.20260729.xlsx. These ranks are not hand-edited; a correction means re-running the fetch against a newer release.
| Realm | Floreoviria |
|---|---|
| Kingdom | Shotokuvirae |
| Phylum | Cossaviricota |
| Class | Papovaviricetes |
| Order | Zurhausenvirales |
| Family | Papillomaviridae |
| Subfamily | Firstpapillomavirinae |
| Genus | Alphapapillomavirus |
| ICTV identifier | ICTV20041459 |
| NCBI taxon | 337042 |
| Exemplar isolate | X05015 |
Host evidence
- human: 3,457 GenBank records
Counts of nucleotide records annotated with that host. Evidence of provenance, not a statement of host range.
Where it occurs
Not searched yet. No country-level occurrence data has been curated for this virus. The WHO reported-case data on this site covers a limited set of diseases; a virus outside it gets no map rather than an empty one.
What it does
quote
Globally, an estimated 662,301 new cervical cancer cases and 348,874 deaths occurred in 2022.
quote
FINDINGS: Globally in 2020, there were an estimated 604 127 cervical cancer cases and 341 831 deaths, with a corresponding age-standardised incidence of 13·3 cases per 100 000 women-years (95% CI 13·3-13·3) and mortality rate of 7·2 deaths per 100 000 women-years (95% CI 7·2-7·3).
Lowest and highest vaccine effectiveness reported: 17% (FUTURE II Study Group 2007 N Engl J Med; All high-grade cervical lesions regardless of HPV type, 15 to 26 years) to 100% (Lehtinen M 2012 Lancet Oncol; CIN3+ associated with HPV-16/18, 15 to 25 years). Two of 38 estimates, each from its own study; not a summary figure.
- Randomised trial
- Controlled observational
What can follow the illness
quote
Type 16 is the cause of approximately 50% of cervical cancers worldwide, and types 16 and 18 together account for about 66% of cervical cancers.
quote
In 143 women managed only by punch or wedge biopsy, cumulative incidence of invasive cancer of the cervix or vaginal vault was 31.3% (95% CI 22.7-42.3) at 30 years, and 50.3% (37.3-64.9) in the subset of 92 such women who had persistent disease within 24 months.
quote
The largest number of cases was attributable to H pylori (n=760 000, PAF 4%), followed by HPV (n=750 000, 4%), HBV (n=360 000, 2%), EBV (n=260 000, 1%), and HCV (n=160 000, <1%).
When problems appear: after the infection, and after the vaccine
Two separate clocks on the same logarithmic scale. The first starts at the infection and shows when its sequelae are described as beginning; the second starts at the dose and shows when the vaccine's adverse events are described as beginning. Each bar is one source's printed window, not a synthesis; hover for the source.
- Product label observation window
- Compensation-table interval
- Study risk window: when events were counted, not typical onset
Disease risk and vaccine efficacy: every estimate with its population, design and the sentence it came from.
Vaccines
| Name | Developer | Platform | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|---|
| Human Papillomavirus 9-valent Vaccine, Recombinant | See FDA listing | Not searched yet | Routine immunisation | Approved | US: approved | — | candidateId fda-human-papillomavirus-9-valent-vaccine-recombinant (tar |
In development
| Name | Developer | Platform | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|---|
| 2 doses of vaccine Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) | National Vaccine and Serum Institute, China | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT06632912 | candidateId ctgov-2-doses-of-vaccine-quadrivalent-recombinant-human-pa |
| 9-valent HPV vaccine (Cecolin 9) | Xiamen Innovax Biotech Co., Ltd | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT07668271 | candidateId ctgov-9-valent-hpv-vaccine-cecolin-9-xiamen-innovax-biotec |
| 9-valent HPV vaccine, 3 doses standard timing | The University of Texas Medical Branch, Galveston | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT05672927 | candidateId ctgov-9-valent-hpv-vaccine-2-doses-alternate-timing-the-un |
| 9vHPV vaccine | Merck Sharp & Dohme LLC | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT05450705 NCT05314023 NCT05285826 | candidateId ctgov-9vhpv-vaccine-merck-sharp-dohme-llc (targetDisease ' |
| BNT113 | BioNTech SE | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT04534205 | candidateId ctgov-bnt113-biontech-se (targetDisease 'HPV'); stage copi |
| Cervavac as two dose regimen | Serum Institute of India Pvt. Ltd. | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT06281119 | candidateId ctgov-cervavac-as-three-dose-regimen-serum-institute-of-in |
| Gardasil-9 | Emory University | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT06799494 | candidateId ctgov-gardasil-9-emory-university (targetDisease 'HPV'); s |
| Gardasil9 | Miriam Elfström | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT04910802 | candidateId ctgov-gardasil9-miriam-elfstr-m (targetDisease 'HPV'); sta |
| HPV nonavalent vaccine (Gardasil-9) | Canadian Immunization Research Network | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT07156084 | candidateId ctgov-hpv-nonavalent-vaccine-gardasil-9-canadian-immunizat |
| HPV vaccine | University of Washington | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT05291871 NCT04235257 | candidateId ctgov-hpv-vaccine-university-of-washington (targetDisease |
| human papillomavirus vaccine, recombinant | Louisiana State University Health Sciences Center in New Orleans | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT05266898 | candidateId ctgov-human-papillomavirus-9-valent-vaccine-recombinant-lo |
| Nonavalent HPV vaccine | University of British Columbia | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT05495906 | candidateId ctgov-nonavalent-hpv-vaccine-university-of-british-columbi |
| Nonavalent HPV vaccine (9vHPV/Gardasil-9™). | Miquel Angel Pavon Ribas | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT05334706 | candidateId ctgov-nonavalent-hpv-vaccine-9vhpv-gardasil-9-miquel-angel |
| Prophylactic quadrivalent HPV vaccine Merck (Gardasil®) | Partha Basu | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT00923702 | candidateId ctgov-prophylactic-quadrivalent-hpv-vaccine-merck-gardasil |
| Recombinant Human Papillomavirus Bivalent Vaccine | National Cancer Institute (NCI) | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT03180034 NCT07706673 NCT05237947 | candidateId ctgov-diphtheria-toxoid-tetanus-toxoid-acellular-pertussis |
| V503 | Merck Sharp & Dohme LLC | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT07785843 | candidateId ctgov-v503-merck-sharp-dohme-llc (targetDisease 'HPV'); st |
| 10vHPV | Serum Institute of India Pvt. Ltd. | Not searched yet | Routine immunisation | Phase 2 | Not searched yet | NCT07888686 | candidateId ctgov-10vhpv-serum-institute-of-india-pvt-ltd (targetDisea |
| V540B (HPV vaccine) | Merck Sharp & Dohme LLC | Not searched yet | Routine immunisation | Phase 1 | Not searched yet | NCT06623409 | candidateId ctgov-gardasil-9-g9-merck-sharp-dohme-llc (targetDisease ' |
| V540D (HPV vaccine) | Merck Sharp & Dohme LLC | Not searched yet | Routine immunisation | Phase 1 | Not searched yet | NCT06688058 | candidateId ctgov-v540d-merck-sharp-dohme-llc (targetDisease 'HPV'); s |
| Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine | Merck Sharp & Dohme LLC | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT00733122 | candidateId ctgov-quadrivalent-human-papillomavirus-types-6-11-16-18-r |
| V502 | Merck Sharp & Dohme LLC | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT00365443 | candidateId ctgov-v502-merck-sharp-dohme-llc (targetDisease 'HPV'); st |
| V540A (V540A-2 / V540A-3) | Merck Sharp & Dohme LLC | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT07224477 | candidateId ctgov-v540a-2-merck-sharp-dohme-llc (targetDisease 'HPV'); |
Antivirals
Not searched yet. No US-approved antiviral for this virus was found in the openFDA drug label endpoint. Only US labels were searched, and only drugs the FDA classes as antivirals.
Antibodies and immune globulins
Not searched yet. No US-approved antiviral antibody for this virus was found in the openFDA drug label endpoint.
Approval status is not a treatment recommendation. Dosing and eligibility are on the label and in national guidelines. This page does not give medical advice and does not render dosing. A development stage is not a measure of how well something works.
Related on this site
- Disease risk and vaccine efficacy — burden figures and trial results, each quoted from its source
- Hpv vaccine — ingredients, schedule and reported side effects
- Vaccine pipeline — candidates listed under “HPV”
- Other Papillomaviridae viruses